

## AD-HOC ANNOUNCEMENT

---

### **STRATEC to acquire hematology system specialist Diatron**

Birkenfeld, March 23, 2016

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX), has entered into an agreement with the global private equity firm The Riverside Company, headquartered in New York and Cleveland governing the full acquisition of Diatron MI PLC, Budapest, Hungary and its US affiliate company. Diatron designs and manufactures system solutions for hematology applications, as well as related consumables. The transaction is expected to close near the end of this month.

The acquisition is expected to be accretive to the Groups earnings in 2016 already. In the past financial year, Diatron generated sales equivalent to around € 34 million with profitability comparable to the STRATEC Group's. The company has about 200 employees, working mainly in development, production and sales at locations in Hungary and the US. Diatron's customers include well-known life science companies with global operations.

Diatron's OEM portfolio chiefly comprises analyzer systems, system components, consumables and tests in the lower throughput segment of hematology. This extension in value creation to the field of decentralized laboratory solutions represents a highly complementary addition to STRATEC's expertise and its product portfolio. Furthermore, STRATEC is diversifying its range of human and veterinary diagnostics products and gaining access to new customers. To date, STRATEC's core competence has involved designing and manufacturing systems for blood grouping and typing, molecular diagnostics, and immunoassays. These areas will now be supplemented with hematology systems. STRATEC expects the takeover to generate synergies, particularly in developing and manufacturing consumables, modules for complete analyzer systems, and smaller systems. STRATEC remains in line with its strategic value of not entering into competition with customers or partners, whether in terms of products or by way of acquisitions.

## Information and notes concerning this ad-hoc announcement:

### Conference call and audio webcast

To report on the acquisition of Diatron we will be holding a conference call in English tomorrow, Thursday, March 24, 2016 at 3.00 p.m. (CET).

To take part in the conference call, please use the following dial-in numbers:

Dial-in numbers:     +49-69-2222-10639 (DE)  
                          +44-20-3427-1925 (UK)  
                          +1-646-254-3376 (USA)  
                          +33-1767-72244 (F)

Conference Code:    1604901

Participants are requested to dial in ten minutes before the conference call starts.

The conference call can also be watched as an audio webcast at [www.stratec.com/audiowebcast201603](http://www.stratec.com/audiowebcast201603) (brief registration required). Please note that no questions can be submitted via audio webcast.

You can also watch and download a slide presentation via audio webcast at [www.stratec.com/audiowebcast201603](http://www.stratec.com/audiowebcast201603) (brief registration required).

### About STRATEC

STRATEC Biomedical AG ([www.stratec.com](http://www.stratec.com)) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

### Further information can be obtained from:

STRATEC Biomedical AG  
André Loy, Corporate Communications  
Gewerbestr. 37, 75217 Birkenfeld  
Germany  
Tel: +49 7082 7916-190  
Fax: +49 7082 7916-999  
[ir@stratec.com](mailto:ir@stratec.com)  
[www.stratec.com](http://www.stratec.com)